[8-K] 10x Genomics, Inc. Reports Material Event

Rhea-AI Filing Summary

10x Genomics (TXG) announced a planned legal leadership transition. Eric S. Whitaker will retire as Chief Legal Officer effective January 1, 2026, after more than eight years with the company. He will remain an employee with reduced compensation and serve as Strategic Counsel, continuing to advise on ongoing legal matters.

Dr. Randy Wu, currently Vice President of Intellectual Property and Litigation, has been appointed General Counsel and Secretary effective January 1, 2026. Wu joined the company in August 2016 following his tenure at Orrick, Herrington & Sutcliffe LLP, and holds a Ph.D. in Biophysics (UCSF) and a J.D. (Stanford). CEO Serge Saxonov highlighted Whitaker’s leadership through key milestones, and emphasized continuity with Wu’s internal promotion.

Insights

Corporate governance analyst

Orderly legal leadership transition with internal successor; neutral impact.

The company disclosed a scheduled change in its top legal role, with Eric S. Whitaker stepping down as Chief Legal Officer on January 1, 2026 and transitioning to Strategic Counsel. This preserves institutional knowledge while shifting day-to-day responsibilities.

Appointing Dr. Randy Wu—an internal leader since August 2016 overseeing IP and litigation—signals continuity across key legal workflows. Educational and professional credentials are detailed, but no compensation figures or additional terms are provided in this excerpt.

The transition is framed as planned and supportive, with leadership commentary underscoring stability. Actual day-to-day impact depends on execution of responsibilities during and after the effective date.

false000177078700017707872025-11-122025-11-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

FORM 8-K

______________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

10x Genomics, Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-39035			45-5614458
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

6230 Stoneridge Mall Road

Pleasanton, California 94588

(925) 401-7300

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

___________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Class A common stock, par value $0.00001 per share

TXG

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

After more than eight years of exemplary service, on November 12, 2025 Eric S. Whitaker announced his intention to retire as Chief Legal Officer of 10x Genomics, Inc. (the “Company”) effective January 1, 2026. Mr. Whitaker will remain an employee of the Company with reduced compensation and assume the position of Strategic Counsel, continuing to provide advice and counsel to the Company in connection with ongoing legal matters.

Dr. Randy Wu, who currently serves as the Company’s Vice President, Intellectual Property and Litigation, has been appointed to succeed Mr. Whitaker as General Counsel and Secretary of the Company effective January 1, 2026. Dr. Wu joined the Company in August 2016 after working as an attorney at Orrick, Herrington & Sutcliffe LLP. Dr. Wu holds a Ph.D. in Biophysics from the University of California, San Francisco, a J.D. from Stanford Law School and an A.B. in Chemistry from Harvard University.

Serge Saxonov, Co-Founder and Chief Executive Officer of the Company, said “Eric has been an extraordinary partner to me and to 10x over the past eight years. From our IPO to navigating complex legal challenges, his leadership, judgment and integrity have helped shape who we are as a company. Beyond his many professional accomplishments, Eric has been a trusted counselor and a steady hand through every major milestone in our journey. I’m deeply grateful for all he’s contributed, and that he’ll continue to be part of 10x as an advisor.”

Saxonov continued, “I’m thrilled to have Randy stepping into the role of General Counsel and Secretary. Randy has been with 10x for nearly a decade and knows our company, our mission and our people inside and out. He’s been integral to many of our biggest milestones and brings deep experience, sound judgment and a calm, practical approach that our teams trust and respect. I’m excited to see him take on this new role and continue building on the strong foundation he’s helped create.”

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			10x Genomics, Inc.
			By:			/s/ Eric S. Whitaker
			Name:			Eric S. Whitaker
			Title:			Chief Legal Officer
Date: November 13, 2025

FAQ

What leadership change did 10x Genomics (TXG) announce?

Eric S. Whitaker will retire as Chief Legal Officer and transition to Strategic Counsel, and Dr. Randy Wu will become General Counsel and Secretary.

When do the TXG legal leadership changes take effect?

Both changes are effective on January 1, 2026.

Will Eric S. Whitaker remain with 10x Genomics after retiring as CLO?

Yes. He will remain an employee with reduced compensation as Strategic Counsel advising on ongoing legal matters.

Who is Dr. Randy Wu, the new General Counsel at TXG?

He is VP of Intellectual Property and Litigation, joined TXG in August 2016, and holds a Ph.D. (UCSF) and J.D. (Stanford).

What titles will Dr. Randy Wu hold at 10x Genomics?

He will serve as General Counsel and Secretary.

Did TXG disclose reasons for the transition?

The company stated it is a retirement after more than eight years of service, with Whitaker moving to an advisory role.